Testing effectiveness (Phase 2)Study completedNCT02365649
What this trial is testing
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy
Who this might be right for
Crohn's Disease
AbbVie 220